Immuron completes strategic investment in leading gut health biotech Ateria Health
November 16, 2022 07:00 ET
|
Immuron Limited
Highlights: Immuron has completed settlement of strategic investment in leading gut health biotech Ateria Health, in accordance with signed subscription and option agreement (announced 13 October...
Immuron CEO, Steven Lydeamore to present at AusBioInvest
October 26, 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron strategic investment in leading gut health biotech Ateria Health
October 13, 2022 06:00 ET
|
Immuron Limited
Highlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of...
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
October 04, 2022 06:00 ET
|
Immuron Limited
Highlights: Clinical Trial Master Service Agreement with US-based Pharmaron ExecutedInvestigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)Plans in...
Immuron CEO, Steven Lydeamore, to host an investor webinar
August 29, 2022 07:00 ET
|
Immuron Limited
MELBOURNE, Australia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for...
Immuron Update on IMM-124E SARS-CoV-2 Research
August 19, 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for...
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic
July 26, 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, July 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron North American Travelan® Sales up 494% and Global sales up 431%
July 11, 2022 06:00 ET
|
Immuron Limited
Highlights: North American FY22 Travelan® sales increased by +494% to $0.6MGlobal sales increased by 431% to $0.9MAustralian FY22 sales increased by 318% to $0.3M MELBOURNE, Australia, July 11,...
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease
July 07, 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic
May 11, 2022 06:00 ET
|
Immuron Limited
Key Points US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA)Two human phase II clinical trials to be conducted. One trial will focus on...